Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.

Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, Armitage J, Collins R; Heart Protection Study Collaborative Group..

Circulation. 2012 May 22;125(20):2469-78. doi: 10.1161/CIRCULATIONAHA.111.073684. Epub 2012 Apr 26.

2.

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.

Heart Protection Study Collaborative Group., Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Peto R, Collins R.

Lancet. 2011 Dec 10;378(9808):2013-20. doi: 10.1016/S0140-6736(11)61125-2. Epub 2011 Nov 22.

3.

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study.

Heart Protection Study Collaborative Group., Jonathan Emberson, Derrick Bennett, Emma Link, Sarah Parish, John Danesh, Jane Armitage, Rory Collins.

Lancet. 2011 Feb 5;377(9764):469-76. doi: 10.1016/S0140-6736(10)62174-5. Epub 2011 Jan 27.

4.

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.

Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, Collins R; Heart Protection Study Collaborative Group..

Circ Cardiovasc Genet. 2011 Feb;4(1):68-73. doi: 10.1161/CIRCGENETICS.110.958371. Epub 2011 Jan 20.

5.

Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality.

Heart Protection Study Collaborative Group..

J Intern Med. 2010 Oct;268(4):348-58. doi: 10.1111/j.1365-2796.2010.02258.x.

6.

Statin cost-effectiveness in the United States for people at different vascular risk levels.

Heart Protection Study Collaborative Group..

Circ Cardiovasc Qual Outcomes. 2009 Mar;2(2):65-72. doi: 10.1161/CIRCOUTCOMES.108.808469. Epub 2009 Mar 5.

8.

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.

Heart Protection Study Collaborative Group., Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R.

J Am Coll Cardiol. 2007 Jan 23;49(3):311-9.

9.

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.

Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R; Heart Protection Study Collaborative Group..

Lancet. 2005 May 21-27;365(9473):1779-85.

PMID:
15910950
11.

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group..

Lancet. 2004 Mar 6;363(9411):757-67.

PMID:
15016485
12.

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group..

Lancet. 2003 Jun 14;361(9374):2005-16.

PMID:
12814710
13.
14.

Supplemental Content

Loading ...
Support Center